Real-World Evidence

Overview

Real-World Data in Oncology

Real-World Evidence in Oncology

Why Do We Need RWE?

RWE vs Clinical Trials

PALOMA-2: Demographics and Baseline Characteristics

PALOMA-3: ITT Population Clinical Characteristics

First-Line CDK4/6 Treatment: Outcomes in Older Women

Pooled Retrospective Subgroup Analysis

Pooled Efficacy and Safety of CDK4/6 Inhibitors

Palbociclib Real-World Insights (IRIS): Real-World Treatment Outcomes in Patients Treated With Palbociclib Combination Therapy

Palbociclib in Highly Pre-Treated Patients With ER+/HER2- MBC

Real-World Insights: Remarks

What Do Phase 4 Trials and Single-Institution Datasets Add to Our Understanding and Clinical Practice?

Practical Strategies for Incorporating RWE

RWE in the Clinic

Clinical Considerations

Dose Modifications

Further Directions

Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Retrospective, Single-Institution Review

Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Efficacy and Safety Results

Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Investigator Conclusions

Everolimus in Postmenopausal HR+ ABC (BOLERO-2): Demographics and Baseline Characteristics

BOLERO-2: Safety Profile

RWE: Everolimus Use in First-Line HR+ MBC

RWE: Everolimus Dosing Patterns

RWE for Everolimus in HR+ MBC

Everolimus and CDK4/6 Inhibitors: Clinical Questions

Alpelisib

RWE on Dose Reductions and Delays for CDK4/6 Inhibitors

Ongoing Observational/RWE Trials With CDK4/6 Inhibitors

Real-World Use of Palbociclib in Patients With HR+/HER2- ABC: Results From POLARIS

Ongoing Observational/RWE Trials With CDK4/6 Inhibitors (cont)

RWD and RWE: Take-Home Messages and Concluding Remarks

Abbreviations

Abbreviations (cont)